Laboratory response to paradigm change in hemophilia treatment: How to monitor patients simultaneously treated with emicizumab and Factor VIII concentrate?

Autor:	Shafaati Lambert, Marjan, Bruzelius, Maria, Mahmoud Hourani Soutari, Nida, Ranta, Susanna, Antovic, Jovan P.
Předmět:	BLOOD coagulation factor VIII EMICIZUMAB HEMOPHILIA treatment BLOOD coagulation factor VIII antibodies PATIENT monitoring BISPECIFIC antibodies
Zdroj:	Clinical Chemistry & Laboratory Medicine; Nov2023, Vol. 61 Issue 12, pe248-e250, 3p
Abstrakt:	In our laboratory FVIII:C CSA with bovine reagents is available 24/7 and if steady-state emicizumab activity is known addition of FVIII exogenous activity observed with this assay may give precise and accurate information about real level of total FVIII activity. Keywords: emicizumab; FVIII concentrate; FVIII:C CSA EN emicizumab FVIII concentrate FVIII:C CSA e248 e250 3 10/30/23 20231101 NES 231101 To the Editor, Treatment of hemophilia A (HA) has been changed dramatically in recent years. [Extracted from the article]
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu